Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma
© 2024 The Author(s)..
Background: Scarce evidence exists for clinical target volume (CTV) definitions of regional lymph nodes (LNs) in intrahepatic cholangiocarcinoma (iCCA) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA). We investigated the mapping pattern of nodal recurrence after surgery for iCCA and cHCC-CCA and provided evidence for the nodal CTV definition.
Methods: We retrospectively reviewed the medical records of patients with iCCA or cHCC-CCA who underwent surgery between 2010 and 2020. Eligibility criteria included patients pathologically diagnosed with iCCA or cHCC-CCA after surgery and a first recurrent event in regional LNs during follow-up. All recurrent LNs were registered onto reference computed tomography images based on the vascular structures to reconstruct the node mapping. Fifty-three patients were eligible. LN regions were classified into four risk groups.
Results: Hepatic hilar and portal vein-vena cava were the most common recurrent regions, with recurrence rates of 62.3 % and 39.6 % (high-risk regions), respectively. Recurrence rates in the left gastric, diaphragmatic, common hepatic, superior mesenteric vessels, celiac trunk, and paracardial regions ranged from 15.1 % to 30.2 % (intermediate-risk regions). There were fewer recurrences in the para-aortic (16a1, a2, b1) and splenic artery and hilum regions, with rates <10 % (low-risk regions). No LN recurrence was observed in the para-oesophageal or para-aortic region (16b2) (very low-risk regions). Based on node mapping, the CTV should include high- and intermediate-risk regions for pathologically negative LN patients during postoperative radiotherapy. Low-risk regions should be included for pathologically positive LN patients.
Conclusion: We provide evidence for CTV delineation in patients with iCCA and cHCC-CCA based on recurrent LN mapping.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Clinical and translational radiation oncology - 45(2024) vom: 19. März, Seite 100749 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Zhuanbo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical target volume |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ctro.2024.100749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369153669 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369153669 | ||
| 003 | DE-627 | ||
| 005 | 20240302232723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctro.2024.100749 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM369153669 | ||
| 035 | |a (NLM)38425471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Zhuanbo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Background: Scarce evidence exists for clinical target volume (CTV) definitions of regional lymph nodes (LNs) in intrahepatic cholangiocarcinoma (iCCA) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA). We investigated the mapping pattern of nodal recurrence after surgery for iCCA and cHCC-CCA and provided evidence for the nodal CTV definition | ||
| 520 | |a Methods: We retrospectively reviewed the medical records of patients with iCCA or cHCC-CCA who underwent surgery between 2010 and 2020. Eligibility criteria included patients pathologically diagnosed with iCCA or cHCC-CCA after surgery and a first recurrent event in regional LNs during follow-up. All recurrent LNs were registered onto reference computed tomography images based on the vascular structures to reconstruct the node mapping. Fifty-three patients were eligible. LN regions were classified into four risk groups | ||
| 520 | |a Results: Hepatic hilar and portal vein-vena cava were the most common recurrent regions, with recurrence rates of 62.3 % and 39.6 % (high-risk regions), respectively. Recurrence rates in the left gastric, diaphragmatic, common hepatic, superior mesenteric vessels, celiac trunk, and paracardial regions ranged from 15.1 % to 30.2 % (intermediate-risk regions). There were fewer recurrences in the para-aortic (16a1, a2, b1) and splenic artery and hilum regions, with rates <10 % (low-risk regions). No LN recurrence was observed in the para-oesophageal or para-aortic region (16b2) (very low-risk regions). Based on node mapping, the CTV should include high- and intermediate-risk regions for pathologically negative LN patients during postoperative radiotherapy. Low-risk regions should be included for pathologically positive LN patients | ||
| 520 | |a Conclusion: We provide evidence for CTV delineation in patients with iCCA and cHCC-CCA based on recurrent LN mapping | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical target volume | |
| 650 | 4 | |a Combined hepatocellular-cholangiocarcinoma | |
| 650 | 4 | |a Intrahepatic cholangiocarcinoma | |
| 650 | 4 | |a Recurrent lymph node mapping | |
| 700 | 1 | |a Wang, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Yirui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shulian |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yongkun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yueping |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yongwen |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Shunan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Ningning |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ye-Xiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational radiation oncology |d 2016 |g 45(2024) vom: 19. März, Seite 100749 |w (DE-627)NLM280595387 |x 2405-6308 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g day:19 |g month:03 |g pages:100749 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctro.2024.100749 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |b 19 |c 03 |h 100749 | ||